Publications by authors named "Scot Middleton"

Claim this Profile
I
Isoform-selective thiazolo[5,4-b]pyridine S1P1 agonists possessing acyclic amino carboxylate head-groups.
Anthony B Reed, Brian A Lanman, Susana Neira, Paul E Harrington, Kelvin K C Sham, Scot Middleton

Bioorg Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: potent S1P₁ agonists with in vivo lymphocyte-depleting activity.
Mike Frohn, Victor J Cee, Brian A Lanman, Alexander J Pickrell, Jennifer Golden, Scot Middleton

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.
Brad Bolon, Marina Stolina, Caroline King, Scot Middleton, Jill Gasser

J Biomed Biotechnol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS.
Ashis K Saha, Xiang Yu, Jian Lin, Mercedes Lobera, Anurag Sharadendu, Scot Middleton

ACS Med Chem Lett· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1).
Brian A Lanman, Victor J Cee, Srinivasa R Cheruku, Mike Frohn, Jennifer Golden, Scot Middleton

ACS Med Chem Lett· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5.
Victor J Cee, Mike Frohn, Brian A Lanman, Jennifer Golden, Kristine Muller, Scot Middleton

ACS Med Chem Lett· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
Marina Stolina, Georg Schett, Denise Dwyer, Steven Vonderfecht, Scot Middleton

Arthritis Res Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.
Marina Stolina, Brad Bolon, Scot Middleton, Denise Dwyer, Heather Brown

J Clin Immunol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis.
Marina Stolina, Brad Bolon, Denise Dwyer, Scot Middleton, Diane Duryea

Biomarkers· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
Brad Herberich, Guo-Qiang Cao, Partha P Chakrabarti, James R Falsey, Liping Pettus, Scot Middleton

J Med Chem· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, Christina Boucher, Lilly Chai, Scot Middleton

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, David C McGowan, David M Armistead, Scot Middleton

J Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.
Marina Stolina, Stephen Adamu, Mike Ominsky, Denise Dwyer, Frank Asuncion, Scot Middleton

J Bone Miner Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the kinetics of osteoclastogenesis in arthritic rats.
Georg Schett, Marina Stolina, Brad Bolon, Scot Middleton, Matt Adlam

Arthritis Rheum· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Nuria Tamayo, Lillian Liao, Martin Goldberg, David Powers, Yan-Yan Tudor, Scot Middleton

Bioorg Med Chem Lett· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
Georg Schett, Scot Middleton, Brad Bolon, Marina Stolina, Heather Brown

Arthritis Rheum· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis